Literature DB >> 23340998

Adenosine signaling during acute and chronic disease states.

Harry Karmouty-Quintana1, Yang Xia, Michael R Blackburn.   

Abstract

Adenosine is a signaling nucleoside that is produced following tissue injury, particularly injury involving ischemia and hypoxia. The production of extracellular adenosine and its subsequent signaling through adenosine receptors plays an important role in orchestrating injury responses in multiple organs. There are four adenosine receptors that are widely distributed on immune, epithelial, endothelial, neuronal,and stromal cells throughout the body. Interestingly, these receptors are subject to altered regulation following injury. Studies in mouse models and human cells and tissues have identified that the production of adenosine and its subsequent signaling through its receptors plays largely beneficial roles in acute disease states, with the exception of brain injury. In contrast, if elevated adenosine levels are sustained beyond the acute injury phase, adenosine responses can become detrimental by activating pathways that promote tissue injury and fibrosis. Understanding when during the course of disease adenosine signaling is beneficial as opposed to detrimental and defining the mechanisms involved will be critical for the advancement of adenosine-based therapies for acute and chronic diseases. The purpose of this review is to discuss key observations that define the beneficial and detrimental aspects of adenosine signaling during acute and chronic disease states with an emphasis on cellular processes, such as inflammatory cell regulation, vascular barrier function, and tissue fibrosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340998      PMCID: PMC3606047          DOI: 10.1007/s00109-013-0997-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  99 in total

1.  Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury.

Authors:  Jonathan B Volmer; Linda F Thompson; Michael R Blackburn
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

2.  Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma.

Authors:  E S L Chan; P Fernandez; A A Merchant; M C Montesinos; S Trzaska; A Desai; C F Tung; D N Khoa; M H Pillinger; A B Reiss; M Tomic-Canic; J F Chen; M A Schwarzschild; B N Cronstein
Journal:  Arthritis Rheum       Date:  2006-08

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor.

Authors:  Melanie L Hart; Almut Grenz; Iris C Gorzolla; Jens Schittenhelm; Julee H Dalton; Holger K Eltzschig
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

5.  Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes.

Authors:  Zequan Yang; Yuan-Ji Day; Marie-Claire Toufektsian; Yaqin Xu; Susan I Ramos; Melissa A Marshall; Brent A French; Joel Linden
Journal:  Circulation       Date:  2006-10-23       Impact factor: 29.690

6.  Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.

Authors:  Edwin S L Chan; Maria Carmen Montesinos; Patricia Fernandez; Avani Desai; David L Delano; Herman Yee; Allison B Reiss; Michael H Pillinger; Jiang-Fan Chen; Michael A Schwarzschild; Scott L Friedman; Bruce N Cronstein
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

7.  Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats.

Authors:  J P Hannon; B Tigani; I Williams; L Mazzoni; J R Fozard
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

8.  A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease.

Authors:  Ankit A Desai; Tong Zhou; Homaa Ahmad; Wei Zhang; Wenbo Mu; Sharon Trevino; Michael S Wade; Nalini Raghavachari; Gregory J Kato; Marlene H Peters-Lawrence; Tejas Thiruvoipati; Kristin Turner; Nicole Artz; Yong Huang; Amit R Patel; Jason X-J Yuan; Victor R Gordeuk; Roberto M Lang; Joe G N Garcia; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

9.  Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action.

Authors:  Lisa K Stamp; Jody Hazlett; Rebecca L Roberts; Christopher Frampton; John Highton; Paul A Hessian
Journal:  Arthritis Res Ther       Date:  2012-06-08       Impact factor: 5.156

10.  Physiological roles for ecto-5'-nucleotidase (CD73).

Authors:  Sean P Colgan; Holger K Eltzschig; Tobias Eckle; Linda F Thompson
Journal:  Purinergic Signal       Date:  2006-06-01       Impact factor: 3.765

View more
  50 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

Review 2.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

Review 3.  Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis.

Authors:  David Lu; Paul A Insel
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-18       Impact factor: 4.249

4.  Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE-/- (Apolipoprotein E Deficient) Mice.

Authors:  Min Zhang; Xianqiu Zeng; Qiuhua Yang; Jiean Xu; Zhiping Liu; Yaqi Zhou; Yapeng Cao; Xiaoyu Zhang; Xiaofei An; Yiming Xu; Lei Huang; Zhen Han; Tao Wang; Chaodong Wu; David J Fulton; Neal L Weintraub; Mei Hong; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

5.  HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.

Authors:  Kemly Philip; Tingting Weng Mills; Jonathan Davies; Ning-Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G Molina; Javier Amione-Guerra; Neeraj Sinha; Ashrith Guha; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2017-07-12       Impact factor: 5.191

Review 6.  Metabolomic and molecular insights into sickle cell disease and innovative therapies.

Authors:  Morayo G Adebiyi; Jeanne M Manalo; Yang Xia
Journal:  Blood Adv       Date:  2019-04-23

Review 7.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

8.  Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.

Authors:  Shraddha Nayak; Md Abdul H Khan; Tina C Wan; Hong Pei; Joel Linden; Melinda R Dwinell; Aron M Geurts; John D Imig; John A Auchampach
Journal:  Purinergic Signal       Date:  2015-09-18       Impact factor: 3.765

9.  Macrophage A2A Adenosine Receptors Are Essential to Protect from Progressive Kidney Injury.

Authors:  Luan D Truong; Jessica Trostel; Rachel McMahan; Jiang-Fan Chen; Gabriela E Garcia
Journal:  Am J Pathol       Date:  2016-08-09       Impact factor: 4.307

10.  Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.

Authors:  Hicham Labazi; Bunyen Teng; Zhichao Zhou; S Jamal Mustafa
Journal:  J Mol Cell Cardiol       Date:  2015-12-02       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.